1/15
01:01 pm
sldb
JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success [Yahoo! Finance]
Low
Report
JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success [Yahoo! Finance]
1/14
12:30 pm
sldb
Solid Biosciences (NASDAQ:SLDB) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
Low
Report
Solid Biosciences (NASDAQ:SLDB) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
1/14
03:53 am
sldb
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 [Yahoo! Finance]
High
Report
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 [Yahoo! Finance]
1/13
04:15 pm
sldb
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
High
Report
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
1/12
04:15 pm
sldb
Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
Medium
Report
Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
1/12
08:27 am
sldb
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia [Yahoo! Finance]
Low
Report
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia [Yahoo! Finance]
1/12
08:05 am
sldb
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
Medium
Report
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
1/6
08:00 am
sldb
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/5
04:15 pm
sldb
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/17
08:45 am
sldb
Solid Biosciences (NASDAQ:SLDB) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
High
Report
Solid Biosciences (NASDAQ:SLDB) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
12/16
05:26 pm
sldb
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services [Yahoo! Finance]
Medium
Report
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services [Yahoo! Finance]
12/16
04:51 pm
sldb
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
Medium
Report
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
12/8
08:00 am
sldb
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
Low
Report
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
12/6
05:47 am
sldb
Solid Biosciences (NASDAQ:SLDB) was upgraded by analysts at Needham & Company LLC to a "moderate buy" rating.
Low
Report
Solid Biosciences (NASDAQ:SLDB) was upgraded by analysts at Needham & Company LLC to a "moderate buy" rating.
12/4
07:19 am
sldb
Solid Biosciences (NASDAQ:SLDB) is now covered by analysts at Needham & Company LLC. They set a "buy" rating on the stock.
High
Report
Solid Biosciences (NASDAQ:SLDB) is now covered by analysts at Needham & Company LLC. They set a "buy" rating on the stock.
12/1
04:05 pm
sldb
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/1
08:00 am
sldb
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Medium
Report
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
11/17
08:21 am
sldb
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 [Yahoo! Finance]
Low
Report
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 [Yahoo! Finance]
11/17
08:00 am
sldb
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101
Neutral
Report
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101
11/11
08:00 am
sldb
Solid Biosciences to Participate at Upcoming Investor Conferences
Medium
Report
Solid Biosciences to Participate at Upcoming Investor Conferences
11/6
08:38 am
sldb
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy [Yahoo! Finance]
Medium
Report
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy [Yahoo! Finance]
11/6
08:00 am
sldb
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy
Medium
Report
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy
11/5
04:03 pm
sldb
Solid Biosciences (NASDAQ:SLDB) had its price target lowered by analysts at Citigroup Inc. from $16.00 to $14.00. They now have a "buy" rating on the stock.
Medium
Report
Solid Biosciences (NASDAQ:SLDB) had its price target lowered by analysts at Citigroup Inc. from $16.00 to $14.00. They now have a "buy" rating on the stock.
11/5
03:27 pm
sldb
Solid Biosciences (NASDAQ:SLDB) had its price target lowered by analysts at JPMorgan Chase & Co. from $13.00 to $11.00. They now have an "overweight" rating on the stock.
Low
Report
Solid Biosciences (NASDAQ:SLDB) had its price target lowered by analysts at JPMorgan Chase & Co. from $13.00 to $11.00. They now have an "overweight" rating on the stock.
11/4
04:05 pm
sldb
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)